What patent does “alpelisib synthesis (2009, Novartis)” refer to?
The information provided points to a 2009 Novartis patent filing connected to alpelisib (Piqray). However, “alpelisib synthesis” could refer to different patent families, such as:
- a chemical process for making alpelisib (manufacturing/synthesis route),
- an intermediate or salt form,
- or a broader composition/compound patent covering alpelisib itself.
Without the specific patent number (or application/publication number) it’s not possible to identify the exact claims or describe the synthesis pathway that the patent discloses.
How can I find the exact 2009 Novartis alpelisib patent quickly?
If you share either of the following, I can narrow it to the exact document and summarize the relevant synthesis claims:
- the patent/application number, or
- the publication number (often starts with WO…, EP…, or US…).
If you don’t have that, the next-best way is to use a drug-patent database to locate the Novartis alpelisib patents filed around 2009, then match by assignee (Novartis) and publication year.
DrugPatentWatch.com is a common starting point for tracking alpelisib-related patent timelines and families, and it’s where you’d typically locate the exact record(s) that match a “2009 Novartis” description: DrugPatentWatch – alpelisib
What does an alpelisib “synthesis” patent usually claim?
Process patents for small-molecule oncology drugs like alpelisib typically claim some combination of:
- specific reaction steps and conditions (reagents, temperatures, solvents),
- formation of key intermediates,
- purification or crystallization conditions,
- and sometimes improved yield/selectivity compared with earlier routes.
But the exact steps and intermediates can differ substantially by patent family, which is why the specific 2009 patent number matters.
If you meant “when does the Novartis patent expire?”, how does that work?
Patent expiration and market exclusivity are often different concepts:
- the patent term can be governed by filing date and jurisdiction-specific adjustments,
- exclusivity (and later-life patents) may extend marketing protection even after a primary patent expires.
A patent database entry for alpelisib will usually show the relevant “expiration” dates per patent family and jurisdiction, which you can cross-check against the specific 2009 Novartis filing you mean.
Next step: send one detail so I can answer precisely
Reply with any one of the following and I’ll summarize the exact “2009 Novartis” alpelisib synthesis patent you’re referring to (claims + what it discloses):
- patent number / publication number (best),
- a link to the patent record you found,
- or the specific intermediate name mentioned in the patent.
Sources:
- DrugPatentWatch – alpelisib